临床误诊误治2026，Vol.39Issue(10)：39-44,6.DOI:10.3969/j.issn.1002-3429.2026.10.007
卡瑞利珠单抗和信迪利单抗治疗晚期食管癌患者的安全性及对预后的影响
Safety and prognostic outcomes of Camrelizumab and Sintilimab therapy in patients with advanced esophageal cancer
摘要
Abstract
Objective To compare the safety of Camrelizumab and Sintilimab on patients with advanced esophageal cancer,and to analyze their prognostic outcomes.Methods A retrospective analysis was conducted on 156 patients with advanced esophageal cancer admitted to our hospital from January 2021 to June 2025.According to the treatment methods received by the patients,they were divided into the Camrelizumab group(n=72)and the Sintilimab group(n=84).The tumor characteristics and occurrence of adverse reactions between the two groups were compared,and the prognosis of the two groups was analyzed.Results There was no significant difference in the levels of carcinoembryonic antigen,tumor location,TNM stage,tumor type,and differentiation grade between the two groups upon admission(P＞0.05).Compared with the Sintilimab group[21.43％(18/84)],the incidence of reactive capillary hyperplasia was significantly increased in the Camrelizumab group[73.61％(53/72)].Kaplan-Meier survival function analysis showed that compared with the Camrelizumab group,the progression-free survival(PFS)of patients in the Sintilimab group was significantly prolonged(P＜0.05);there was no significant difference in overall survival between the two groups(P＞0.05).Sintilimab significantly prolonged the PFS of patients with TNM stage Ⅳ disease(P＜0.05).Conclusion Camrelizumab and Sintilimab have comparable adverse reaction rates in patients with advanced esophageal cancer,but Sintilimab significantly prolongs PFS.关键词
食管肿瘤/卡瑞利珠单抗/信迪利单抗/反应性毛细血管增生症/总生存率/无进展生存期Key words
esophageal cancer/Camrelizumab/Sintilimab/reactive cutaneous capillary endothelial proliferation/overall survival rate/progression-free survival引用本文复制引用
施朕善,何妍筱,李子木,王强强,李思仪..卡瑞利珠单抗和信迪利单抗治疗晚期食管癌患者的安全性及对预后的影响[J].临床误诊误治,2026,39(10):39-44,6.基金项目
中华国际医学交流基金会先声临床科研专项基金项目(Z-2014-06-18388) （Z-2014-06-18388）
